Generic Name: linagliptin
More frequent side effects include: hypoglycemia.  See below for a comprehensive list of adverse effects.
Applies to linagliptin: oral tablet
As well as its needed effects, linagliptin (the active ingredient contained in Tradjenta) may cause unwanted side effects that require medical attention. 
If any of the following side effects occur while taking linagliptin, check with your doctor immediately:
Some linagliptin side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:


Applies to linagliptin: oral tablet
Uncommon (0.1% to 1%): Constipation, increased amylase levelsFrequency not reported: PancreatitisPostmarketing reports: Acute pancreatitis[Ref]
During clinical trials, pancreatitis was reported in 15.2 cases per 10,000 patient year exposure in patients receiving linagliptin compared with 3.7 cases per 10,000 patient year exposure in those receiving active comparator (sulfonylurea).  Following completion of clinical trials, 3 additional cases of pancreatitis were reported among those receiving linagliptin.  Postmarketing reports of acute pancreatitis, including fatalities, have been received.[Ref]
The most common adverse event reported was nasopharyngitis.[Ref]
Serious hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions have been reported postmarketing in patients treated with this drug.  These reactions have occurred within the first 3 months, with some occurring after the first dose.[Ref]
Frequency not reported: Drug hypersensitivityPostmarketing reports: Serious hypersensitivity reactions[Ref]
Common (1% to 10%): Hypoglycemia, hypertriglyceridemia, hyperlipidemia, increased uric acid[Ref]
The incidence of hypoglycemia in patients treated with this drug as monotherapy, or in combination with metformin or pioglitazone, was similar to the incidence observed in placebo-treated patients.  When given in combination with metformin plus a sulfonylurea, the incidence of hypoglycemia was almost 23% compared to 15% in those receiving placebo with metformin plus a sulfonylurea.  As add-on to stable insulin therapy, the incidence of hypoglycemia was similar to placebo (31.4% versus 32.9%).[Ref]
Postmarketing reports of bullous pemphigoid requiring hospitalization have been reported with dipeptidyl peptidase-4 (DPP-4) inhibitors use.  These case typically recovered with topical or systemic immunosuppressive treatment and discontinuation of DPP-4 inhibitor.[Ref]
Postmarketing reports: Rash, angioedema, urticariaDipeptidyl peptidase-4 inhibitors:Postmarketing reports: Bullous pemphigoid[Ref]
Common (1% to 10%): Cough, nasopharyngitis, upper respiratory tract infection[Ref]
Between October 2006 and December 2013, thirty-three cases of severe arthralgia have been reported to the FDA Adverse Event Reporting System Database.  Each case involved the use of 1 or more dipeptidyl peptidase-4 (DPP-4) inhibitor.  In all cases, substantial reduction in prior activity level was reported, 10 patients were hospitalized due to disabling joint pain.  In 22 cases, symptoms appeared within 1 month of starting therapy, in 23 cases symptoms resolved less than 1 month after discontinuation.  A positive rechallenge was reported in 8 cases, with 6 cases involving use of a different DPP-4 inhibitor.  Sitagliptin had the greatest number of cases reported (n=28) followed by saxagliptin (n=5), linagliptin (the active ingredient contained in Tradjenta) (n=2), alogliptin (n=1), and vildagliptin (n=2).[Ref]
Common (1% to 10%): Back pain, arthralgia, extremity pain[Ref]
Common (1% to 10%): Headache[Ref]
Common (1% to 10%): Urinary tract infection[Ref]
1. "Product Information. Tradjenta (linagliptin)." Boehringer Ingelheim, Ridgefield, CT. 
2. Cerner Multum,  Inc. "Australian Product Information." O 0
3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
4. US Food and Drug Administration "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf."   ([2015, Aug 28]):
It is possible that some side effects of Tradjenta may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Anxiety
blurred vision
chills
cold sweats
coma
confusion
cool, pale skin
depression
dizziness
fast heartbeat
headache
increased hunger
nausea
nightmares
seizures
shakiness
slurred speech
unusual tiredness or weakness


Bloating
constipation
cough
fever
hives, welts, itching, or skin rash
large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
loss of appetite
pains in the stomach, side, or abdomen, possibly radiating to the back
puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
redness of the skin
severe joint pain


Muscle aches
sore throat
stuffy or runny nose


Diarrhea

